The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss

Vorinostat, an oral histone deacetylase inhibitor with anti-tumor activity, is in clinical trials for hematological and solid tumors that metastasize and compromise bone structure. Consequently, there is a requirement to establish the effects of vorinostat on tumor growth within bone. Breast (MDA-23...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pratap, Jitesh, Akech, Jacqueline, Wixted, John J., Szabo, Gabriela, Hussain, Sadiq, McGee-Lawrence, Meghan E., Li, Xiaodong, Bedard, Krystin, Dhillon, Robinder J., van Wijnen, Andre J., Stein, Janet L., Stein, Gary S., Westendorf, Jennifer J., Lian, Jane B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3059237/
https://ncbi.nlm.nih.gov/pubmed/21159607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0572
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados